Distribution of β -carotene-encapsulated polysorbate 80-coated poly(D, L-lactide-co-glycolide) nanoparticles in rodent tissues following intravenous administration

Taiki Miyazawa^{1,2}
 Kiyotaka Nakagawa^{1,2}
 Takahiro Harigae²
 Ryo Onuma²
 Fumiko Kimura²
 Tomoyuki Fujii³
 Teruo Miyazawa^{4,5}

¹Vascular Biology Laboratory, Jean Mayer USDA (United States Department of Agriculture)-Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA;

²Food and Biodynamic Chemistry Laboratory, ³Terahertz Optical & Food Engineering Laboratory, Graduate School of Agricultural Science, ⁴Food and Biotechnology Innovation Project, New Industry Creation Hatchery Center (NICHe), ⁵Food and Health Science Research Unit, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan

Purpose: Biodegradable nanoparticles (NPs) composed of poly(D, L-lactide-co-glycolide) (PLGA) have attracted considerable attention as delivery systems of drugs and antioxidative compounds, such as β -carotene (BC). Intravenous (IV) administration of BC-containing PLGA-NPs (BC-PLGA-NPs) coated with polysorbate 80 (PS80) has been shown to effectively deliver BC to the brain. However, the whole-body distribution profile of BC is still not clear. Therefore, we investigated the accumulation of BC in various organs, including the brain, following IV administration of PS80-coated BC-PLGA-NPs in rats.

Methods: PS80-coated and uncoated BC-PLGA-NPs were prepared by solvent evaporation, and administered intravenously to Sprague Dawley rats at a BC dose of 8.5 mg/rat. Accumulation of BC in various organs (brain, heart, liver, lungs, and spleen) and blood plasma was evaluated by high performance liquid chromatography with ultraviolet (UV) detection, 1 hour after administration.

Results: We prepared PS80-coated BC-PLGA-NPs with an entrapment efficiency of 14%, a particle size of 260 nm, and a zeta potential of -26 mV. Coating with PS80 was found to result in significant accumulation of BC in the lungs, rather than in the brain and other tissues. Further, plasma levels of BC in the PS80-coated BC-PLGA-NP group were much lower than those of the uncoated BC-PLGA-NP group.

Conclusion: Following IV administration, PS80-coated BC-PLGA-NPs are quickly transferred from plasma circulation to the lungs, rather than the brain. Significant accumulation of BC in the lungs may be useful for health-related applications.

Keywords: β -carotene, intravenous administration, nanoparticles, poly(D, L-lactide-co-glycolide) (PLGA), polysorbate 80 (PS80), tissue distribution

Introduction

Use of biodegradable polymer-based nanoparticles (NPs) for drug delivery purposes can result in enhanced distribution of drugs to target organs.¹ One of the most attractive biodegradable polymers used for the preparation of NPs is poly(D, L-lactide-co-glycolide) (PLGA).² PLGA undergoes hydrolysis in the body to produce the naturally occurring monomers lactic acid and glycolic acid.³

Intravenous (IV) administration of PLGA-based NPs (PLGA-NPs) coated with nonionic surfactants has been shown to result in accumulation in specific tissues.⁴ For example, IV administration of polysorbate 80 (PS80)-coated PLGA-NPs results in significant uptake by the brain.⁵⁻⁷ However, to the best of our knowledge, few studies have investigated the effect of PS80 coating on whole-body tissue distribution of NPs.

Correspondence: Kiyotaka Nakagawa
 Food and Biodynamic Chemistry
 Laboratory, Graduate School of
 Agricultural Science, Tohoku University,
 1-1 Tsutsumidori-Amamiyamachi,
 Aobaku, Sendai 981-8555, Japan
 Tel +81 22 717 8906
 Fax +81 22 717 8905
 Email nkgw@m.tohoku.ac.jp

PLGA were added to 2 mL of dichloromethane in a 10 mL glass tube and vortexed for 10 minutes to dissolve them. Next, 4 mL of 5% (w/v) PVA aqueous solution was added and vortexed for 10 seconds. The resultant mixture was sonicated at 40% amplitude for 3 minutes using a sonic dismembrator, and added dropwise into 100 mL of 0.3% (w/v) PVA aqueous solution under rapid stirring. The resultant oil-in-water emulsion was stirred for 9 hours in a fume hood to allow the dichloromethane solvent to evaporate. The suspension was centrifuged at $2,000\times g$ for 10 minutes at 4°C to remove larger aggregates. The supernatant was collected, filtered through a membrane filter, washed three times with Milli-Q water by centrifugation, and finally resuspended in 3 mL of Milli-Q water either with or without 5% (w/v) sucrose.¹² The resulting BC-PLGA-NP suspension was lyophilized and stored in the dark at -30°C . PLGA-NPs were prepared similarly, without addition of BC.

Surface morphology of BC-PLGA-NPs (lyophilized powder) was evaluated by SEM (SU8000 Type II, Hitachi Co., Ltd, Tokyo, Japan).¹² The effect of sucrose addition on the surface microstructure was also investigated. Lyophilized BC-PLGA-NPs, PLGA-NPs, and free BC powder (100 mg each) were suspended in 3 mL of distilled water and photographed. To measure EE, BC was extracted from the BC-PLGA-NPs by a mixture of ethanol and hexane.⁹ The amount of BC in each extract was determined by HPLC-UV as described in the following section. EE was calculated as follows: $\text{EE (\%)} = \frac{\text{BC}_{\text{encapsulated}}}{\text{BC}_{\text{total}}} \times 100$.¹³

Preparation of PS80-coated BC-PLGA-NPs: diameter and zeta potential analysis

BC-PLGA-NPs (lyophilized powder, 100 mg) were resuspended in 3 mL of distilled water containing 1% PS80, and incubated for 30 minutes to coat the BC-PLGA-NPs with PS80.^{6,7,14} Uncoated BC-PLGA-NPs were prepared similarly without addition of PS80. Uncoated PLGA-NPs were also prepared. All suspensions were subjected to DLS and laser Doppler anemometry measurement using ELS-Z (Otsuka Electronics Co., Ltd., Osaka, Japan) to evaluate the mean diameters and zeta potentials, respectively.

Animal study

Nine male Sprague Dawley rats (12 weeks of age, 410–580 g body weight) were obtained from CLEA (Central Laboratory for Experimental Animals) Japan Inc. (Tokyo, Japan) and housed in cages kept at 23°C with a 12-hour light:dark cycle. The rats were acclimated with commercial rodent chow (CE-2; CLEA Japan Inc.) and water for 1 week. After acclimatization, rats were fasted for 14 hours,

followed by IV administration of 2.4 mL of PS80-coated BC-PLGA-NPs suspension, uncoated BC-PLGA-NPs suspension, or control saline into the rat tail vein, at a BC dose of 8.5 mg/rat (equivalent sum of BC from the three preparations). Rats were sacrificed by decapitation 1 hour after administration, and organs (brain, heart, liver, lungs, and spleen) were harvested. Blood was collected in ethylenediaminetetraacetic acid (EDTA)-coated tubes, and centrifuged at $1,000\times g$ for 15 minutes at 4°C to prepare the plasma samples. Harvested organs and plasma were stored at -80°C until further analysis. The experimental protocol was reviewed by the Committee on the Ethics of Animal Experiments and carried out in accordance with the Animal Experiment Guidelines of Tohoku University. The permit number for this animal experiment is 23-Noudou-23.

BC was extracted from organ samples as follows:¹⁵ organs were homogenized with saline (containing 1 mM EDTA) to prepare 20% (w/v) homogenate solution. The solution (0.5 mL) was mixed with 2.6 mL of ethanol (containing 0.9 mol/L potassium hydroxide and 0.05 mol/L pyrogallol). The mixture was saponified at 80°C for 2 hours. After addition of 2 mL of distilled water, BC was extracted from the resultant mixture using 3 mL of hexane/diethyl ether (3:1, v/v). The extract was partitioned into two layers by centrifugation at $1,000\times g$ for 10 minutes at 4°C . The upper hexane layer was collected, and the extraction was repeated. The layers were combined, dried under nitrogen gas, resuspended in a small amount of methanol/methyl tert-butyl ether (MTBE) (2:3, v/v), and subjected to BC analysis by HPLC-UV. For plasma BC analysis, plasma (0.5 mL) was mixed with 0.5 mL of distilled water, 1 mL of ethanol, and 3 mL of hexane.¹⁶ The mixture was centrifuged at $1,000\times g$ for 10 minutes at 4°C . The upper hexane layer was collected, and the extraction was repeated. The layers were combined, dried, resuspended in a small amount of methanol/MTBE (2:3, v/v), and subjected to analysis by HPLC-UV. These extraction procedures were conducted under subdued (yellow) light to minimize photodegradation of BC.

HPLC-UV determination of BC in sample extract

Sample extract was analyzed by HPLC-UV.¹⁷ A C_{30} carotenoid column (4.6 $\times$ 250 mm, 5 μm ; YMC, Kyoto, Japan) was used, and the extract was eluted using a binary gradient consisting of the following HPLC solvents: A, methanol/MTBE/water (83:15:2 [v/v/v], containing 3.9 mmol/L ammonium acetate); B, methanol/MTBE/water (8:90:2 [v/v/v], containing 2.6 mmol/L ammonium acetate). The gradient profile was

as follows: B linear ratio; 10%–55% at 0–12 minutes, 55%–100% at 12–20 minutes, 100% at 20–25 minutes, and 100%–10% at 25–27 minutes. The flow rate was adjusted to 1 mL/min, and the column temperature was maintained at 30°C. The column eluent was sent to a UV detector (UV-2075 PLUS, JASCO, Tokyo, Japan) for BC monitoring at 463 nm. Concentrations of BC were calculated using the equation corresponding to the standard curve.

Statistical analysis

Results are reported as mean $\pm$ SD. Statistical significance between the PS80-coated and uncoated BC-PLGA-NP groups was analyzed using the independent Student's *t*-test. Mean significantly differed at $P < 0.05$ and $P < 0.01$.

Results

Surface morphology and EE analysis of BC-PLGA-NPs

BC-PLGA-NPs were prepared by solvent evaporation, and suspended in water in either the presence or absence of a cryoprotectant (sucrose). SEM images of the BC-PLGA-NP suspension lyophilized in the absence of sucrose revealed spherical aggregates (Figure 2A). Lyophilization in the presence of sucrose, on the other hand, resulted in the BC-PLGA-NPs being immobilized in the sucrose matrix, with no evidence of aggregation (Figure 2B). We therefore used sucrose for the preparation of lyophilized BC-PLGA-NPs in this study.

Dispersion of lyophilized powder of PLGA-NPs in distilled water resulted in a transparent homogeneous suspension with white color (Figure 3A). In contrast, dispersion of BC-PLGA-NPs resulted in orange homogeneous suspension

(Figure 3B). The EE of BC in the BC-PLGA-NPs was estimated to be $14.2\% \pm 0.3\%$ ($n=3$, Table 1). Free BC powder was very difficult to disperse and showed a deep red color (Figure 3C).

Mean diameter and zeta potential analysis of PS80-coated BC-PLGA-NPs

BC-PLGA-NPs were coated with PS80 by incubation in water containing 1% PS80. Mean diameters and zeta potentials of all preparations were nearly identical (Table 1). Mean diameters of PS80-coated BC-PLGA-NPs, uncoated BC-PLGA-NPs, and uncoated PLGA-NPs were found to be 259 ± 62 nm, 286 ± 93 nm, and 256 ± 25 nm ($n=3$), respectively. Zeta potentials of each of the preparations were -26.36 ± 0.98 mV, -29.92 ± 3.25 mV, and -29.31 ± 2.73 mV ($n=3$), respectively. The resultant PS80-coated and uncoated BC-PLGA-NPs were employed to evaluate the brain uptake and tissue distribution of BC in rats.

Brain uptake and tissue distribution of BC following IV administration of PS80-coated BC-PLGA-NPs

Rats were intravenously administered with suspensions of PS80-coated or uncoated BC-PLGA-NPs, or saline control. Before IV administration, we did not reduce excess PS80 in the solution because several reports showed brain uptake of PS80-coated NPs with this manner.^{5–7,14} One hour after administration, blood plasma was collected and organs were harvested, and the corresponding concentrations of BC were determined by HPLC-UV (Figure 4). No detectable levels of BC were found in the plasma or any of the organs of rats that received saline (control).

Figure 2 SEM images of lyophilized BC-PLGA-NPs in the presence and absence of 5% (w/v) sucrose.

Notes: (A) Lyophilized BC-PLGA-NPs in the absence of sucrose. (B) Lyophilized BC-PLGA-NPs in the presence of 5% (w/v) sucrose.

Abbreviations: BC-PLGA-NPs, β -carotene-encapsulated poly(D, L-lactide-co-glycolide) nanoparticles; SEM, scanning electron microscope.

Figure 3 Photographs of NPs and control suspensions.

Notes: Lyophilized products were redispersed in distilled water and mixed for 5 minutes, and then photographed. **(A):** PLGA-NPs lyophilized with 5% (w/v) sucrose. **(B):** BC-PLGA-NPs lyophilized with 5% (w/v) sucrose. **(C):** Free BC powder in distilled water.

Abbreviations: BC, β -carotene; BC-PLGA-NPs, β -carotene-encapsulated poly(D, L-lactide-co-glycolide) nanoparticles; NPs, nanoparticles; PLGA-NPs, poly(D, L-lactide-co-glycolide) nanoparticles.

In contrast, no significant differences of brain BC concentration were found between BC-PLGA-NP and PS80-coated BC-PLGA-NP groups. These unexpected findings suggest that coating with PS80 did not have an impact on BC brain uptake. On the other hand, concentrations of BC in the lungs and plasma were significantly higher and lower, respectively, in the PS80-coated BC-PLGA-NP group, compared with the uncoated BC-PLGA-NP group. Increased levels of BC were also found in the heart, liver, and spleen in the PS80-coated BC-PLGA-NP group, compared with the uncoated group. Taken together, these results suggest that PS80-coated BC-PLGA-NPs were quickly transferred from the circulation to the lungs, rather than to the brain, while uncoated BC-PLGA-NPs were not distributed to the lungs and remained in circulation.

Discussion

BC (Figure 1A) exhibits antioxidative properties and plays an important role in protecting cellular membrane lipids from

oxidative stress in the body.¹⁸ Recently, encapsulation of BC in PLGA-NPs has been carried out in an effort to improve its therapeutic effects. For example, Yusuf et al prepared PS80-coated BC-PLGA-NPs and found that IP administration in rats significantly increased BC concentrations in the brain.⁹ However, they did not evaluate the distribution of BC into other organs. Elucidating the whole-body distribution of BC is important to gauge the usefulness of encapsulation methods and PS80 coating. To clarify these aspects, we prepared PS80-coated BC-PLGA-NPs and uncoated BC-PLGA-NPs, and investigated the brain uptake and tissue distribution profiles of BC following IV administration in rats.

BC-PLGA-NPs were lyophilized in the presence of sucrose, and the resultant BC-PLGA-NPs were immobilized (protected) in the sucrose matrix (Figure 2B). This is consistent with results of a previous study,¹² in which SEM investigation of the surface morphology of PLGA-NPs revealed the protective effects of sucrose during the lyophilization process. In this study, the lyophilized powder (BC-PLGA-NPs) was well-dispersed in water, with no apparent aggregation (Figure 3B). Thus, lyophilization of BC-PLGA-NPs in the presence of sucrose is recommended to obtain well-dispersed BC-PLGA-NPs.

The EE of drugs in PLGA-NPs is generally reported to be approximately 45%.¹³ In the present study, the EE of BC was found to be rather low (14.2%), which may be due to aggregation of the BC-PLGA-NPs during preparation. Specifically, we prepared BC-PLGA-NPs by solvent evaporation. During the solvent (dichloromethane) evaporation process, visible aggregates of BC were observed. Additional studies are needed to focus on optimizing the amounts of PLGA and PVA to overcome this problem.

Coating with PS80 did not impact the mean diameter and zeta potential of NPs. Specifically, the mean diameter (286 nm) and zeta potential (-29.9 mV) of the BC-PLGA-NPs were found to be similar to those of general PLGA-NPs prepared by solvent evaporation.^{5-7,13} As a point of reference, Ribeiro et al prepared polysorbate 20 (PS20)-coated BC-PLGA-NPs by solvent evaporation of an oil-in-water emulsion comprising PS20.¹⁹ Using this same procedure, Yusuf et al prepared PS80-coated BC-PLGA-NPs.⁹ While these methods are useful for surface coating, it is nearly impossible to produce uncoated BC-PLGA-NPs, so that comparisons between PS80-coated and uncoated BC-PLGA-NPs cannot be performed. In this study, we first prepared uncoated BC-PLGA-NPs, and then incubated the resulting BC-PLGA-NPs with PS80 to allow for surface coating.^{6,7,14} Both coated and uncoated BC-PLGA-NPs were administered

Table 1 Physicochemical parameters of the PS80-coated BC-PLGA-NPs, uncoated BC-PLGA-NPs, and uncoated PLGA-NPs

Groups	Mean diameter (nm)	Zeta potential (mV)	Encapsulation efficiency (%)
PS80-coated BC-PLGA-NPs	259 $\pm$ 62	-26.36 ± 0.98	14.2 $\pm$ 0.3
Uncoated BC-PLGA-NPs	286 $\pm$ 93	-29.92 ± 3.25	
Uncoated PLGA-NPs	256 $\pm$ 25	-29.31 ± 2.73	

Note: Values represent mean $\pm$ SD, n=3.

Abbreviations: BC-PLGA-NPs, β -carotene-encapsulated poly(D, L-lactide-co-glycolide) nanoparticles; PLGA-NPs, poly(D, L-lactide-co-glycolide) nanoparticles; PS80, polysorbate 80.

Figure 4 BC concentrations in the organs and plasma of rats after IV administration of saline control, uncoated BC-PLGA-NPs, and PS80-coated BC-PLGA-NPs.

Notes: BC concentrations in organs and plasma were analyzed 1 hour after IV administration (mean $\pm$ SD, $n=3$). Data were calculated using the value given by the independent Student's *t*-test between the PS80-coated and uncoated BC-PLGA-NP groups. Mean significantly differed at $*P<0.05$ and $**P<0.01$.

Abbreviations: BC, β -carotene; BC-PLGA-NPs, β -carotene-encapsulated poly(D, L-lactide-co-glycolide) nanoparticles; PS80, polysorbate 80; IV, intravenous.

intravenously to rats, allowing for a direct comparison of their distribution profiles in various tissues.

Generally, rodents exhibit very low tissue BC concentrations in the body.²⁰ Consistent with this, no detectable levels of BC were found in the brain and other tissues in the control group (Figure 4). Blood plasma was collected and organs were harvested 1 hour after administration, since previous *in vivo* studies found higher brain uptake of PS80-coated PLGA-NPs at this time point.^{5,7} In this study, however,

the PS80-coated BC-PLGA-NP group did not result in higher concentrations of BC in the brain (Figure 4, brain). So far, only two published studies^{5,6} have compared PS80-coated and uncoated PLGA-NPs having similar mean diameters (approximately 250 nm) to the NPs used herein. Both studies, indeed, revealed increased brain uptake of PS80-coated PLGA-NPs. However, mannitol was used as the cryoprotectant for the preparation of the NPs in these studies. As mannitol is known as a transient blood–brain barrier opener,²¹

further studies are needed to clarify the effect of mannitol on the brain uptake of PS80-coated BC-PLGA-NPs.

Plasma BC concentrations in the PS80-coated BC-PLGA-NP group were found to be much lower than those in the uncoated BC-PLGA-NP group (Figure 4, plasma). Such prolonged circulation effect of uncoated BC-PLGA-NPs was reported by Tsai et al¹³ using curcumin-encapsulated uncoated PLGA-NPs (approximately 160 nm in diameter). Considering the release profile, Capurso et al¹⁰ prepared retinoic acid-encapsulated PLGA-NPs (approximately 250 nm in diameter) with a similar procedure to us. They found 20% of retinoic acid was released from PLGA-NPs within 10 hours of incubation in phosphate-buffered saline. Therefore, in the present study, we deduced that approximately 20% of BC from BC-PLGA-NPs may be released. But, almost all of BC were still encapsulated in NPs within 1 hour. On the other hand, the PS80-coated BC-PLGA-NP group tended to result in higher BC accumulation in other organs (Figure 4, heart, liver, and spleen). Interestingly, BC concentrations in the lungs in the PS80-coated BC-PLGA-NP group were much higher than those in the uncoated BC-PLGA-NP group (Figure 4, lung). Löbenberg et al reported that PS80-coated hexyl-cyanoacrylate (encapsulating azidothymidine) NPs (approximately 230 nm in diameter) exhibited a similar tissue distribution profile.²² In general, microparticles (larger than 7 μ m) are known to significantly accumulate in the lungs following IV administration.²³ As the PS80-coated BC-PLGA-NPs used in the present study were on the nanoscale (approximately 260 nm in diameter), it is difficult to speculate that their sizes could affect BC accumulation in the lungs. Considering together the results of previous studies^{4,24} and the present findings, both the accumulation of BC in the lungs and the unique tissue distribution observed for BC (Figure 4) may be explained by distinct binding of apolipoproteins (eg, apolipoprotein E) to the surface of PS80-coated or uncoated BC-PLGA-NPs in circulation. Coating with PS80 may induce the binding of certain apolipoproteins to the surface of BC-PLGA-NPs, thereby enhancing their uptake into macrophage-rich organs, such as the lungs. Further investigations of longer time study (such as 6 or 12 hours) are needed to clarify these phenomenon. Moreover, Pradeep and Kuttan reported that IP administration of BC suspended in gum acacia solution inhibited lung metastasis in mice,²⁵ suggesting that our results (ie, improvement of BC levels in the lungs using PS80-coated BC-PLGA-NPs) may have health-related applications. Also, our finding would enable the use of other beneficial carotenoids such as α -carotene, astaxanthin, β -cryptoxanthin, lutein, lycopene, and neoxanthin.

Conclusion

BC-PLGA-NPs were successfully prepared by solvent evaporation. Addition of sucrose was found to prevent aggregation of the BC-PLGA-NPs during the lyophilization process. PS80-coated BC-PLGA-NPs resulted in significant accumulation of BC in the lungs 1 hour after IV administration, suggesting that PS80-coated BC-PLGA-NPs are quickly transferred from the circulation to the lungs. Uncoated BC-PLGA-NPs, on the other hand, revealed prolonged plasma circulation. Taken together, these results suggest that coating the surface of BC-PLGA-NPs with PS80 can significantly change the entire tissue distribution profile. Further, increased accumulation of BC in the lungs may be useful for the treatment of pulmonary disease.

Acknowledgment

This work was supported in part by KAKENHI (15K14725) of the Japan Society for the Promotion of Science, Japan.

Disclosure

Taiki Miyazawa was supported by Japan Society for the Promotion of Science Postdoctoral Fellowships for Research Abroad (<http://www.jsps.go.jp/>). The authors report no other conflicts of interest in this work.

References

- Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol Pharm*. 2008;5(4):505–515.
- Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. *J Control Release*. 2012;161(2):505–522.
- Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids Surf B Bioint*. 2010; 75(1):1–18.
- Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. *Adv Drug Deliv Rev*. 2009;61(6):428–437.
- Tahara K, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. *Eur J Pharm Biopharm*. 2011; 77(1):84–88.
- Gelperina S, Maksimenko O, Khalansky A, et al. Drug delivery to the brain using surfactant-coated poly (lactide-co-glycolide) nanoparticles: influence of the formulation parameters. *Eur J Pharm Biopharm*. 2009; 74(2):157–163.
- Chaturvedi M, Molino Y, Sreedhar B, Khrestchatsky M, Kaczmarek L. Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood-brain barrier. *Int J Nanomedicine*. 2014;9:575–588.
- Gonnet M, Lethuaut L, Boury F. New trends in encapsulation of liposoluble vitamins. *J Control Release*. 2010;146(3):276–290.
- Yusuf M, Khan RA, Khan M, Ahmed B. Plausible antioxidant biomechanics and anticonvulsant pharmacological activity of brain-targeted β -carotene nanoparticles. *Int J Nanomedicine*. 2012;7: 4311–4321.

10. Capurso NA, Look M, Jeanbart L, et al. Development of a nanoparticulate formulation of retinoic acid that suppresses Th17 cells and upregulates regulatory T cells. *Self Nonself*. 2010;1(4):335–340.
11. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion. *Int J Pharm*. 1999;187(2):143–152.
12. Tang KS, Hashmi SM, Shapiro EM. The effect of cryoprotection on the use of PLGA encapsulated iron oxide nanoparticles for magnetic cell labeling. *Nanotechnology*. 2013;24(12):125101.
13. Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nanoformulation: the kinetics of tissue distribution and blood-brain barrier penetration. *Int J Pharm*. 2011;416(1):331–338.
14. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. *J Control Release*. 2011;154(1):103–107.
15. Lunetta JM, Zulim RA, Dueker SR, et al. Method for the simultaneous determination of retinol and beta-carotene concentrations in human tissues and plasma. *Anal Biochem*. 2002;304(1):100–109.
16. Lyan B, Azais-Braesco V, Cardinault N, et al. Simple method for clinical determination of 13 carotenoids in human plasma using an isocratic high-performance liquid chromatographic method. *J Chromatogr B Biomed Sci Appl*. 2001;751(2):297–303.
17. Miyazawa T, Nakagawa K, Miyazawa T. Liquid chromatography-based assay for carotenoids in human blood. In: Preedy VR, editor. *Vitamin A and Carotenoids: Chemistry, Analysis, Function and Effects, Series of Food and Nutritional Compounds in Focus*. Cambridge, UK: Royal Society of Chemistry; 2012:184–203 (ISBN: 9781849733687).
18. Nakagawa K, Fujimoto K, Miyazawa T. β -Carotene as a high-potency antioxidant to prevent the formation of phospholipid hydroperoxides in red blood cells of mice. *Biochim Biophys Acta*. 1996;1299(1):110–116.
19. Ribeiro HS, Chu BS, Ichikawa S, Nakajima M. Preparation of nanodispersions containing β -carotene by solvent displacement method. *Food Hydrocolloids*. 2008;22(1):12–17.
20. Ribaya-Mercado JD, Holmgren SC, Fox JG, Russell RM. Dietary beta-carotene absorption and metabolism in ferrets and rats. *J Nutr*. 1989;119(4):665–668.
21. Brown RC, Eggleston RD, Davis TP. Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. *Brain Res*. 2004;1014(1–2):221–227.
22. Löbenberg R, Araujo L, Briesen HV, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. *J Control Release*. 1998;50(1–3):21–30.
23. Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. *Adv Drug Deliv Rev*. 2008;60(8):863–875.
24. Sempf K, Arrey T, Gelperina S, et al. Adsorption of plasma proteins on uncoated PLGA nanoparticles. *Eur J Pharm Biopharm*. 2013;85(1):53–60.
25. Pradeep CR, Kuttan GE. Effect of β -Carotene on the inhibition of lung metastasis in mice. *Phytomedicine*. 2003;10(2–3):159–164.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-nanomedicine-journal>

Dovepress

Journal Citation Reports/Science Edition, EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.